Table 2.
Characteristics by exposure to cyclophosphamide (CTX) (n = 120)
| Variables | Exposure to CTX |
P values* | ||
|---|---|---|---|---|
| No CTX (n = 20) | Prior CTX (n = 43) | Concurrent CTX (n = 55) | ||
| Sex | 0.004 | |||
| Female | 75% | 60% | 38% | |
| ANCA Type | <0.0001 | |||
| MPO/P—ANCA | 15% | 56% | 31% | |
| PR3/C—ANCA | 40% | 44% | 67% | |
| ANCA negative | 40% | 0% | 2% | |
| PR3- and MPO-ANCA2 | 5% | 0% | 0% | |
| Organ | ||||
| Lung | 10% | 51% | 62% | 0.0002 |
| ENT | 35% | 49% | 55% | 0.34 |
| Kidney | 45% | 73% | 64% | 0.99 |
| Months of prednisone prior to remission, n/N | 13/20 | 27/43 | 34/55 | 0.11 |
| Median (IQR) | 4.8 (3, 8.9) | 10.9 (9, 30) | 10.5 (3.9, 19) | |
| Months of prednisone prior to first relapse, n/N | 6/20 | 16/43 | 19/55 | 0.54 |
| Median (IQR) | 6.4 (5.7, 18.5) | 14.6 (6.7, 38.5) | 15 (3.6, 26) | |
| Deaths | 5% | 5% | 9% | 0.63 |
CTX, cyclophosphamide; ANCA, antineutrophil cytoplasmic autoantibodies; MPO, myeloperoxidase; PR3, proteinase 3; P, perinuclear, cytoplasmic; C, cytoplasmic; IQR, interquartile range.
*P values were calculated by Fisher's exact test for categorical variables and Wilcoxon two-sample test for continuous variables.